ALERT: Your health is top priority. We’re committed to providing reliable COVID-19 resources to keep you informed and safe.

Endo to Settle 1,300 Testosterone Lawsuits for $200 Million


Editors carefully fact-check all Drugwatch content for accuracy and quality.

Drugwatch has a stringent fact-checking process. It starts with our strict sourcing guidelines.

We only gather information from credible sources. This includes peer-reviewed medical journals, reputable media outlets, government reports, court records and interviews with qualified experts.

Signing a settlement agreement

Endo International will pay $200 million to settle 1,300 lawsuits over Testim. The company disclosed the deal June 12, 2018. The agreement is to resolve “all known” testosterone lawsuits against the company.

Testim is a testosterone therapy drug. Endo’s subsidiary Auxilium manufactures Testim. GlaxoSmithKline co-promotes the drug.

Endo announced in February it would seek a deal.

About 900 of the Testim lawsuits are part of a multidistrict litigation. MDLs combine several similar lawsuits to save time and money in court. A federal panel combined the lawsuits in an Illinois federal court.

The testosterone MDL includes more than 6,000 testosterone lawsuits against Endo, Eli Lilly and AbbVie. The companies manufacture different testosterone therapy products.

The outcome of early trials in an MDL can lead both sides to shape settlements. These trials are known as bellwether trials.

Lilly settled 400 Axiron lawsuits earlier this year. AbbVie lost two testosterone lawsuits over its AndroGel product. The verdicts totaled $143 million. AbbVie faces more bellwether trials in the MDL.

Lawsuits Blame Testosterone Therapy for Heart Attacks, Strokes & Death

Testosterone lawsuits blame Endo and other testosterone makers for cardiovascular injuries. Some men reported heart attacks and strokes after beginning Testim. Others cited deep vein thrombosis and pulmonary embolism. Widows of men on testosterone drugs filed lawsuits for their husbands’ sudden deaths.

People suing Endo and other manufacturers claim the companies over-sold their drugs’ benefits in ads. And that the companies ignored testosterone side effects.

The FDA approved testosterone therapy only for treating hypogonadism. It’s a medical condition in which a man’s body fails to make enough testosterone.

But lawsuits claim manufacturers pushed “off label” uses of the drugs. They accuse companies of promoting testosterone therapy as treatment for flagging male sex drives. Plaintiffs say the companies also promoted the drugs as treatment for normal aging conditions.

The lawsuits allege testosterone drugs offered little benefit for the off-label uses. But the medicine raised the risks of deadly side effects.

Endo Moved to Settle After Winning Testosterone Verdict

Endo won its first bellwether trial in late 2017. But the company immediately pursued a settlement with all the people who sued.

Endo set $200 million aside for the deal late last year. The move puts the rest of its bellwether trials on hold.

The company noted the money it set aside in federal financial filings. It said the $200 million would be cheaper than fighting future lawsuits in court.

The company faced stiff financial pressure to settle. FiercePharma reported that Endo has lost most of its market value in recent years. It also faces hundreds of lawsuits from cities and counties over the opioid crisis.

Terry Turner
Written By Terry Turner Writer

Terry Turner has been writing articles and producing news broadcasts for more than 25 years. He covers FDA policy, proton pump inhibitors, and medical devices such as hernia mesh, IVC filters, and hip and knee implants. An Emmy-winning journalist, he has reported on health and medical policy issues before Congress, the FDA and other federal agencies. Some of his qualifications include:

  • American Medical Writers Association (AMWA) and The Alliance of Professional Health Advocates member
  • Centers for Disease Control and Prevention Health Literacy certificates
  • Original works published or cited in Washington Examiner, MedPage Today and The New York Times
  • Appeared as an expert panelist on hernia mesh lawsuits on the BBC
Edited By
Emily Miller
Emily Miller Managing Editor

6 Cited Research Articles writers follow rigorous sourcing guidelines and cite only trustworthy sources of information, including peer-reviewed journals, court records, academic organizations, highly regarded nonprofit organizations, government reports and interviews with qualified experts. Review our editorial policy to learn more about our process for producing accurate, current and balanced content.

  1. Sagonowsky, E. (2018, June 12). After Setting Aside $200M, Endo Settles 1,300 Testosterone Liability Lawsuits. FiercePharma. Retrieved from
  2. U.S. Judicial Panel on Multidistrict Litigation. (2018, May 15). MDL Statistics Report. Retrieved from
  3. Packel, D. (2018, January 3). Judge Sets Busy Trial Slate for Philly Testosterone Cases. Retrieved from
  4. Feeley, J. & Hanna, J. (2018, February 23). Endo, Glaxo to Settle Suits over Testosterone-Replacement Drugs. Retrieved
  5. U.S. Securities and Exchange Commission. (2018, May 8). Form 10-Q; Endo International PLC. Endo International. Retrieved from
  6. Kumar, P. et al. (2010, July-September). Male hypogonadism: Symptoms and treatment. Retrieved from
View All Sources
Who Am I Calling?

Calling this number connects you with one of Drugwatch's trusted legal partners. A law firm representative will review your case for free.

Drugwatch's sponsors support the organization’s mission to keep people safe from dangerous drugs and medical devices. For more information, visit our sponsors page.

(888) 645-1617